iShares Biotechnology ETF (NASDAQ:IBB) Share Price Break Below Fifty Day Moving Average – Time to Sell?

iShares Biotechnology ETF (NASDAQ:IBB – Get Free Report) shares passed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $208.87 and traded as low as $207.62. iShares Biotechnology ETF shares last traded at $207.98, with a volume of 2,289,353 shares trading hands.

iShares Biotechnology ETF Price Performance

The stock’s 50 day moving average is $208.86 and its two-hundred day moving average is $187.41.

iShares Biotechnology ETF Cuts Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 18th. Investors of record on Tuesday, September 15th were issued a dividend of $0.0112 per share. The ex-dividend date was Tuesday, September 15th. This is a drop from iShares Biotechnology ETF’s previous quarterly dividend of $0.0238. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.0%.

Institutional Investors Weigh In On iShares Biotechnology ETF

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE increased its position in iShares Biotechnology ETF by 10.8% in the first quarter. Bank of America Corp DE now owns 7,259,501 shares of the financial services provider’s stock worth $1,225,767,000 after buying an additional 707,343 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of iShares Biotechnology ETF by 188.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 3,397,078 shares of the financial services provider’s stock valued at $715,187,000 after buying an additional 2,220,901 shares during the last quarter. Royal Bank of Canada grew its stake in shares of iShares Biotechnology ETF by 1.0% during the 1st quarter. Royal Bank of Canada now owns 737,128 shares of the financial services provider’s stock worth $124,464,000 after acquiring an additional 7,434 shares during the period. Jefferies Financial Group Inc. grew its stake in shares of iShares Biotechnology ETF by 38.1% during the 3rd quarter. Jefferies Financial Group Inc. now owns 417,500 shares of the financial services provider’s stock worth $87,896,000 after acquiring an additional 115,194 shares during the period. Finally, Commonwealth Equity Services LLC increased its holdings in iShares Biotechnology ETF by 1.3% in the 3rd quarter. Commonwealth Equity Services LLC now owns 139,653 shares of the financial services provider’s stock worth $29,401,000 after acquiring an additional 1,819 shares during the last quarter. Institutional investors and hedge funds own 62.45% of the company’s stock.

iShares Biotechnology ETF Company Profile

(Get Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Stories

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.